FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
HOUSTON, Feb. 07, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer of Bio-Path Holdings, will present a corporate overview at the upcoming 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 11:00 a.m. ET in New York, NY.
A live webcast of the presentation can be accessed under “Presentations and Publications” in the Media section of the Company’s website at www.biopathholdings.com or at http://www.veracast.com/webcasts/bio/ceoinvestor2017/21213158973.cfm.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations, Inc. 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
